Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Nontuberculous Mycobacterial Infection Market Size Outlook: How Fast Will Revenue Grow Through 2030?
The market for nontuberculous mycobacterial infections experienced robust expansion recently. Projections indicate a rise from $14.96 billion in 2025 to $15.87 billion in 2026, reflecting a compound annual growth rate of 6.1%. Factors contributing to this growth during the historical period included a substantial prevalence of pulmonary infections, a scarcity of viable treatment options, protracted timelines for diagnosing nontuberculous mycobacteria, dependence on standard antibiotic treatments, and insufficient awareness among medical practitioners.
The market for nontuberculous mycobacterial infections is poised for significant expansion over the upcoming years, projecting a valuation of $21.01 billion by 2030, driven by a compound annual growth rate of 7.3%. This anticipated growth trajectory is fueled by several key factors, including the escalating use of combination therapies involving macrolides and rifampin, greater accessibility to aminoglycoside treatments, the burgeoning field of individualized medical approaches, the widening reach of hospital and specialized pharmacy services, and the ongoing innovation in AI-driven diagnostic and patient monitoring technologies. Furthermore, prevailing trends shaping this market include a greater embrace of macrolide and rifampin-based treatment strategies, increased utilization of aminoglycosides, the progressive adoption of multifaceted drug regimens, a broader deployment of sophisticated diagnostic instruments, and the continuous integration of artificial intelligence for monitoring treatment efficacy.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13020&type=smp
Nontuberculous Mycobacterial Infection Market Expansion Supported By Key Demand Factors
The increasing incidence of Chronic Obstructive Pulmonary Disease (COPD), a long-term lung condition defined by ongoing and typically worsening airflow obstruction, is anticipated to be a primary catalyst for the expansion of the nontuberculous mycobacterial (NTM) infection market. Individuals suffering from COPD are more susceptible to NTM infections, which in turn lead to a more pronounced decrease in forced expiratory volume in one second (FEV1) and a higher frequency of exacerbations. The compromised lung tissue and weakened immune system often associated with COPD create an environment conducive to NTM bacterial colonization. Evidence from Public Health Scotland in September 2024 highlighted that for the 2022/23 period, COPD presented with an incidence rate of 112.4 per 100,000 females and 109.7 per 100,000 males, based on hospital admissions and mortality data within Scotland. Consequently, the growing burden of COPD directly fuels the market’s advancement in addressing nontuberculous mycobacterial infections.
Nontuberculous Mycobacterial Infection Market Categorization By Product Type And Application
The nontuberculous mycobacterial infection market covered in this report is segmented –
1) By Drug Class: Macrolides, Rifampin, Aminoglycoside, Other Drug Classes
2) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Macrolides: Azithromycin, Clarithromycin, Erythromycin
2) By Rifampin: Rifampin Monotherapy, Rifampin Combination Therapy, Extended-Duration Rifampin Therapy
3) By Aminoglycoside: Amikacin, Streptomycin, Tobramycin
4) By Other Drug Classes: Fluoroquinolones, Ethambutol, Linezolid, Clofazimine
Nontuberculous Mycobacterial Infection Market Growth Trends Influencing Competitive Dynamics
The dominant players within the nontuberculous mycobacterial infection market are dedicating their efforts to creating cutting-edge treatments, specifically boron-based antibiotics, with the objective of boosting treatment effectiveness, combating resistance, and achieving better results for patients. These boron-based antibiotics function as small-molecule agents that successfully hinder bacterial protein production, presenting strong and more secure alternatives for challenging infections. Illustrating this trend, AN2 Therapeutics, a pharmaceutical firm based in the United States, commenced patient enrollment for the Phase 3 segment of its crucial Phase 2/3 clinical investigation of epetraborole in September 2023. This trial targets individuals with treatment-resistant Mycobacterium avium complex lung disease, following the completion of Phase 2 enrollment. Epetraborole, conceived for oral intake, has shown promise in early research for treating Mycobacterium abscessus infections, with its development aiming to shorten treatment timelines, increase patient comfort, and fulfill critical gaps in the treatment of uncommon and severe respiratory infections, ultimately contributing to superior patient care and control over the condition.
Nontuberculous Mycobacterial Infection Market Company Landscape And Strategic Competition
Major companies operating in the nontuberculous mycobacterial infection market are Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Lupin Limited, Insmed Incorporated, Paratek Pharmaceuticals Inc., Spero Therapeutics Inc., Aradigm Corporation, Dauntless Pharmaceuticals Inc., Validus Pharmaceuticals LLC, Savara Inc, Mannkind Corporation, Matinas BioPharma Holdings Inc, Vast Therapeutics Inc, Crestone Inc, AN2 Therapeutics Inc, Revimmune Inc, Shionogi Co Ltd, Summit Therapeutics plc, BioVersys AG, RedHill Biopharma Ltd, Shanghai MicuRx Pharmaceutical Co Ltd, Otsuka Pharmaceutical Co Ltd, Cipla Limited, Daiichi Sankyo Company Ltd.
Access The Complete Nontuberculous Mycobacterial Infection Market Report:
Nontuberculous Mycobacterial Infection Market Regional Analysis And Leading Geography
North Americawas the largest region in the nontuberculous mycobacterial infection market in 2025. North Americais expected to be the fastest-growing region in the forecast period. The regions covered in the nontuberculous mycobacterial infection market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
